食管癌前细胞DNA、端粒酶含量及多基因表达产物的定量检测

为探讨食管癌高发区人群食管上皮癌变过程中的早期分子改变及早期癌变机理.应用流式细胞术和免疫荧光技术及碘化丙啶DNA荧光染色方法,对食管上皮癌前细胞的DNA含量、端粒酶含量和多个基因p53、p16、cyclin D1蛋白质表达进行了定量检测.检测结果发现,DNA含量在癌变形成时明显增加,异倍体率为87.9%;p53蛋白积聚发生在癌变早期,在癌细胞组的阳性率为100%（5/5）;抑癌基因p16在癌变早期有明显缺失;癌基因cyclin D1及端粒酶阳性率在癌细胞组都为100%（分别为6/6,7/7）.研究结果表明：在癌变早期,DNA含量及异倍体率增加,癌基因cyclin D1表达增高,抑癌基因p16缺失及p53蛋白积聚,端粒酶含量也明显增高,在癌形成时已有多个分子事件发生.     

乳腺癌及良性乳腺组织p185和p16蛋白表达的免疫组织化学研究

应用免疫组化S P法检测了 37例良性乳腺组织 (非上皮增生组 17例、上皮增生组 2 0例 )和 5 9例乳腺癌组织中癌基因蛋白 p185和抑癌基因 p16蛋白的表达状况。结果显示非上皮增生组、上皮增生组和癌的p185阳性率分别为 0 %、15 %和 47%(p <0 0 1) ;p16阳性率分别为 41%、30 %和 34%。p185和p16的表达无明显相关性。乳腺癌早期的 p185过表达和p16失表达率高于浸润性导管癌。两者的阳性率均随组织学级别的增高和瘤体的增大而呈上升趋势 ,但 p >0 0 5。淋巴结转移组的p185阳性率 ( 6 4%)明显高于无淋巴结转移者 ( 32 %) ,p <0 0 5。表明 p185过表达和p16失表达在乳腺癌的发生发展中各自发挥独立的作用。p185是乳腺癌重要的肿瘤标志物。     

细胞凋亡调控因子基因在食管上皮癌变过程中的表达及其意义

目的研究细胞凋亡调控因子Fas、Fasl、Fadd和Caspase 8基因在食管上皮癌变过程中的表达及其意义。方法应用免疫组化S-P法检测食管黏膜中Fas、Fasl、Fadd和Caspase 8的蛋白表达。应用碘化丙啶染色和间接免疫荧光标记方法,采用流式细胞仪对食管黏膜组织进行定量检测。结果从食管正常黏膜组织到不典型增生组织和食管癌组织,Fas、Fadd和Caspase 8蛋白表达率呈逐渐下降的趋势,Fasl蛋白表达率呈逐渐上升的趋势,在食管癌和正常组织之间差异有统计学意义,x^2分别为5．659,7．73,6．32,5．65,P〈0．05或P〈0．01。Fas、Fasl和Caspase 8蛋白高中分化鳞癌中蛋白阳性表达率显著高于低分化鳞癌,两者差异有统计学意义,x^2分别为4．88,7．79,4．68,P〈0．05。与正常黏膜组织和不典型增生组织相比,癌组织中DNA含量明显增高,异倍体细胞显著增加;Fas、Fadd和Caspase 8蛋白表达水平明显降低,t值分别为8．131,7．39,5．44,Fasl基因蛋白表达水平升高,t值为6．671。结论Fas与Fasl的表达失衡与食管癌的发生、发展有密切关系,并与食管癌的分化和免疫逃避有关。Fadd与Caspase8基因表达异常在食管癌的发生发展中可能起着重要作用。食管上皮癌变过程中,DNA含量及异倍体率增加。     

直结肠癌BUBR1的过度表达与TP53突变及微卫星状态关系提示其过度表达与染色体不稳定表型有关

在有丝分裂过程中BUBR1监视微管与着丝点的结合,是保证染色体均等分离的重要分子机制之一.BUBIB变异家谱研究及其敲除模型的研究表明,BUBR1缺陷与染色体不稳定性及肿瘤的发生直接相关.近来在数种人类肿瘤,对BUBR1蛋白过度表达有所报道.但在直结肠癌,BUBR1的过度表达是否与染色体不稳定性的发生有关目前仍无定论.在人类结直肠癌的遗传不稳定性主要表现为两种类型,染色体不稳定性及微卫星不稳定性,它们提示了两条独立的肿瘤发生路径.一般认为不存在高频度微卫星不稳定性表型的肿瘤通过染色体不稳定途径癌变.P53蛋白通过多种机制对维护遗传稳定性起到重要的作用,TP53基因突变经常与染色体不稳定现象并存.DNA倍体情况也是染色体不稳定研究不可缺少的指标.本研究采用免疫组织化学法检测了一组93例进展期散发结直肠癌BUBR1蛋白的表达情况,直接测序法检测TP53变异.高分辨率荧光标记微卫星不稳定检测技术检测微卫星状态,固相激光扫描细胞仪技术检测DNA倍体情况.我们分析了BUBR1表达与三种反映遗传背景的因子的关系.BUBR1蛋白过度表达在人结直肠癌较为常见.在非高频度微卫星不稳定的结直肠癌,BUBR1蛋白过度表达率明显为高(P＜0.01),在TP53基因突变的病例其过度表达率亦较高(P＜0.05).BUBR1蛋白的过度表达与DNA异倍体无统计学相关,但DNA异倍体病例的BuBRl过度表达有偏高倾向.BuBRl表达情况与常用的临床病理学指标无统计学相关.BuBRl过度表达同微卫星状态及TP53突变的关系明确的提示,在人类散发结直肠癌,BUBR1蛋白过度表达与染色体不稳定状态有关.BUBR1过度表达作为一种常见的分子异常,对于肿瘤的早诊预防提供新的标志物.并可能成为治疗的新靶点.     

染色质免疫沉淀技术分析肺腺癌A549细胞中p53蛋白与p21CIP1和Bim基因转录启动子的结合

为了检测肺腺癌A549细胞内抑癌蛋白p53与CDK抑制蛋白p21CIP1和Bim基因转录调控区的结合情况,采用染色质免疫沉淀技术,用p53特异性抗体沉淀DNA,PCR检测p21CIP1和Bim基因5′端特异性序列.结果表明,在抗体免疫沉淀的DNA片段中扩增出p21CIP1和Bim基因5′端的特异性序列.因此证实在A549细胞内,p53蛋白可与p21CIP1和Bim基因转录启动子的特异区域结合,进而参与两基因的表达调控.     

cyclin D1, cyclin E 在乳腺良、恶性病变中的表达及其与p16,p21waf1及Rb 蛋白的关系

为探讨cyclinD1,cyclinE在乳腺癌发生发展中的作用及其与细胞周期调控相关基因蛋白的关系,采用免疫组化检测17例非增生乳腺导管上皮、19例不同程度增生的导管上皮及59例乳腺癌中cyclinD1,cyclinE,p16,p21waf1及Rb基因蛋白的表达.结果显示1.非增生乳腺导管上皮除1例cyclinE过表达外均无cyclinD1和cyclinE的过表达.乳腺癌的cyclinD1和cyclinE的过表达率均明显高于良性乳腺组织(P<0.05).2.乳腺癌cyclinD1过表达与淋巴结转移呈正相关(P<0.05),瘤体直径大于5cm者cyclinE过表达呈增加趋势,但差异无显著性意义.3.CyclinD1和cyclinE的过表达呈正相关(P<0.05).4.从非增生乳腺导管上皮到增生直至乳腺癌,p16,p21与cyclinD1,cyclinE含量的比值逐渐递减,而p21含量高于cyclinD1的乳腺癌体积小、淋巴结转移率低(P<0.05).p21阳性率与cyclinD1过表达呈正相关(P<0.01),也随cyclinE的过表达呈上升趋势.Rb基因蛋白的强表达与cyclinD1过表达呈正相关(P<0.01).结果表明CyclinD1和cyclinE蛋白过表达频发于乳腺癌早期,它们可能与p16、p21waf1、pRb共同参与了乳腺癌的发生发展.     

食管鳞癌p53、c-erbB-2蛋白表达研究

为探讨p53、c-erbB-2蛋白表达与食管鳞癌生物学行为的关系,应用免疫组化LSAB法研究181例食管鳞癌中p53、c-erbB-2蛋白的表达。结果发现,正常食管粘膜均无p53、c-erbB-2蛋白的表达。47％食管鳞癌出现p53表达,p53阳性病例癌旁非典型增生上皮出现p53表达,p53阴性病例癌旁非典型增生上皮亦为阴性。p53阳性表达率与患年龄、性别、肿瘤大小、组织学分级,临床TNM分期无关,且与预后无关。51.4%食管鳞癌呈现c-erbB-2蛋白表达,癌旁非典型增生上皮无c-erbB-2表达。c-erbB-2阳性率与肿瘤组织学分级、浸润深度、淋巴结转移及肝转移有关,c-erbB-2阳性表达预后较差。结果提示,p53表达在食管鳞癌发生中起重要作用;c-erbB-2表达在食管鳞癌浸润转移中起重要作用。同时进行p53、c-erbB-2蛋白免疫组化检测,有助于对食管鳞癌进行早期诊断,监测病情和判断预后。     

胃癌和非癌病变ras P21表达的定量研究

应用流式细胞术对胃癌和胃粘膜的非癌病变组织细胞ras癌基因蛋白产物P²¹表达进行了定量研究,并探讨了ras P²¹表达与DNA倍体与增殖指数的关系.结果表明,胃癌P²¹表达量明显高于非癌病变组织的表达量.胃粘膜非癌病变组织中,胃癌前病变组织P²¹表达量明显高于慢性萎缩性胃炎组织的表达量,并发现P²¹蛋白的表达量与胃癌和癌前病变组织学分级、DNA倍体、增殖指数密切相关.     

染色质免疫沉淀技术分析肺腺癌A549细胞中p53蛋白与p21^CIPI和Bim基因转录启动子的结合

为了检测肺腺癌A549细胞内抑癌蛋白p53与CDK抑制蛋白p21^CIPI和Bim基因转录调控区的结合情况,采用染色质免疫沉淀技术,用p53特异性抗体沉淀DNA,PCR检测p21^CIPI和Bim基因5’端特异性序列。结果表明,在抗体免疫沉淀的DNA片段中扩增出p21^CIPI和Bim基因5’端的特异性序列。因此证实在A549细胞内,p53蛋白可与p21^CIPI和Bim基因转录启动子的特异区域结合,进而参与两基因的表达调控。     

p16和cyclinD1在乳腺导管非典型增生癌变过程中的表达

目的 探讨乳腺导管非典型增生癌变过程中p16和cyclinD1的变化及其相互关系。方法 应用免疫组织化学方法检溯p16、cyclin成在乳腺各组病变中的蛋白表达情况。结果 乳腺导管单纯性增生、非典型增生组织中p16蛋白表达率明显高于乳腺癌组织,差异有显性。cyclinD1在中,重度非典型增生组表达最为明显,且与乳腺导管单纯性增生组及轻度非典型增生组比较,差异均有显性。p16、cyclinD1蛋白在乳腺各组病变中表达呈负相关关系。结论 p16、cyclinDl在乳腺增生性病变中呈现不同程度表达,其表达强度在一定程度上与细胞的恶性倾向有关,检测其表达水平可作为乳腺导管非典型增生组织恶性转化的一个客观检测指标。其中,cyclinD1蛋白可能是乳腺癌发生过程中的早期分子事件,可作为临床早期发现乳腺癌的免疫学指标。     

绿茶对人胃癌细胞株中p21,p53蛋白表达的影响

应用免疫细胞化学方法检测ＳＧＣ—７９０１胃癌细胞株中ｐ２１、ｐ５３蛋白的表达,以探讨绿茶的抗癌作用机理。结果表明：绿茶提取物明显抑制ＳＧＣ—７９０１胃癌细胞株中ｐ２１ｒａｓ、ｐ５３蛋白的表达,并有剂量效应。提示绿茶对ｐ２１、ｐ５３基因突变可能有修复作用     

Quercetin inhibited DNA synthesis and induced apoptosis associated with increase in c-fos mRNA level and the upregulation of p21WAF1CIP1 mRNA and protein expression during liver regeneration after partial hepatectomy

Quercetin, a widely distributed bioflavonoid, inhibited DNA synthesis in regenerating liver after partial hepatectomy. This inhibition was accompanied by apoptosis, evidenced by in situ end-labeling and gel electrophoresis of DNA fragmentation. Characteristic DNA fragmentation was detected as early as 2 h after injection. Northern blot analysis revealed that quercetin induced the increases in c-fos and p21WAF1CIP1 mRNA levels within 2 h. The expression of p21 protein was also enhanced, while p53 mRNA and protein levels were not affected by quercetin. These results suggest that quercetin-induced apoptosis is associated with the increase in c-fos mRNA level and the upregulation of p21 mRNA and protein expression, probably in a p53-independent pathway.     

Mutation and expression of the p53 gene during chemical hepatocarcinogenesis in F344 rats

Inactivation of the p53 gene is one of the most frequent genetic alterations in carcinogenesis. We studied gene mutations, the mRNA expression of p53, and the accumulation of p53 protein in chemical hepatocarcinogenesis in rats. Samples consisting of 44 precancerous foci and 18 cancerous foci were collected by laser capture microdissection (LCM), and analyzed for mutations in rat p53 gene exons 5-8 by PCR-single-strand conformational polymorphism (PCR-SSCP). We found that 25 PCR-SSCP bands of exons 6/7 and 8 were altered in 22/62 (35.4%) LCM samples. Direct p53 gene sequencing showed that 20/62 (9 precancer, 11 cancer) (32.3%) LCM samples exhibited 34 point mutations. Ten LCM samples exhibited double or triple mutations in exons 6/7 and 8 simultaneously. A quantitative analysis of p53 mRNA showed that p53 mRNA peaked at an early stage (week 6) in the precancerous lesion, 20 times that of adjacent normal tissue, and returned to normal by week 23. Similar to precancer, p53 mRNA in cancer was five times as high as that of adjacent normal tissue at week 12, and was closer to normal at week 23. When p53 mRNA declined from a high to low, positive immunostaining for the p53 protein began to be seen in precancerous and cancerous foci, suggesting that the p53 protein had accumulated in these foci. Results show that p53 gene mutation is present in initial chemical hepatocarcinogenesis and p53 mRNA concentration is clearly elevated before gene mutation. Once the p53 gene has mutated, mRNA concentration progressively declines, suggesting that mutation leads to inactivation of the p53 gene.     

p53突变蛋白在胃癌组织中的表达及免疫电镜观察

作者应用抗ｐ５３单克隆抗体Ｐａｂ１８０１（Ａｂ２美国癌基因公司产品）对３８例手术切除的胃癌组织及癌旁胃粘膜的冰冻切片标本进行ｐ５３突变蛋白表达的检测,并进一步用胶体全免疫电镜技术对ｐ５３突变蛋白的分布特征进行观察。结果：３８例胃癌组织中,２４例有ｐ５３突变蛋白高表达,阳性率６３．２％。在对应的癌旁胃粘膜中１０例为ｐ５３的弱表达,正常组织无表达。伴有淋巴结转移的２３例胃癌标本中,１８例ｐ５３高表达（７８．３％）。免疫电镜结果表现,ｐ５３蛋白主要分布于核内染色质中,胞浆中有散在的阳性区,但以核膜周边为主,紧靠核膜。本研究结果提承胃癌的发生及其肿瘤的生物学行为与抑癌基因ｐ５３的突变密切相关,ｐ５３突变蛋白可能是通过对ＤＮＡ复制的影响而参与肿瘤的形成。     

胃癌组织中HER2 基因及p53蛋白表达及其临床意义

目的:研究胃癌组织中HER2基因及P53蛋白表达情况,分析其对临床诊疗的意义与价值。方法:选取2013年7月到2015年7月我院确诊的胃癌患者110例,检测患者胃癌组织中的HER2蛋白表达与基因扩增,及P53蛋白的表达情况,分析HER2基因扩增与P53蛋白表达与病理关系间的关系。结果:HER2基因扩增率为17.3%(19/110),HER2蛋白表达率为42.7%(47/110),P53蛋白表达率为58.2%(64/110),其中HER2蛋白表达3+、2+者HER2基因的扩增比例分别为3/4、6/9与1+表达者的3/16比较具有统计学意义(P0.05);HER2基因扩增和P53蛋白表达与胃癌淋巴结转移以及浸润程度有关(P0.05);相关性分析显示:HER2基因扩增与P53蛋白表达具有正相关关系(P0.05)。结论:胃癌组织中HER2基因扩增和P53蛋白协同表达,促进胃癌浸润和淋巴结转移,对胃癌早期诊断具有重要参考价值。     

DNA ploidy, Ki-67 and p53 as indicators of lymph node metastasis in early gastric carcinoma

OBJECTIVE: To perform flow cytometric and immunohistochemical analysis of early gastric carcinoma in order to investigate the clinical value of DNA ploidy, Ki-67 and p53 as indicators of lymph node metastasis. STUDY DESIGN: We studied 108 cases of surgically resected early gastric carcinoma, which comprised 21 cases showing positive lymph node metastasis (group A) and 87 cases showing negative lymph node metastasis (group B). RESULTS: Aneuploidy was seen in 16 cases (76.2%) in group A in contrast to 10 cases (11.5%) in group B (P = .0029). The mean value of the Ki-67 labeling rate in all cases was 21.9%, and 15 cases (79.0%) showed a Ki-67 labeling rate of more than 21.9% in group A, while they numbered 31 (37.4%) in group B (P = .0016). Cases with cell positive for p53 protein numbered 15 (75%) in group A, while they numbered 38 (46%) in group B (P = .0460). CONCLUSION: DNA aneuploidy, a high labeling rate of Ki-67 and overexpression of p53 are all useful indicators of lymph node metastasis in patients with early gastric carcinoma.     

Evaluation of the cyclin-dependent kinase inhibitor p21Cip1 in epithelial ovarian tumors of low malignant potential and adenocarcinomas

OBJECTIVE: In view of the controversial information on the significance of the cyclin-dependent kinase inhibitor p21Cip1 in ovarian cancer, we conducted a retrospective investigation to clarify the relationships of this protein to proliferation rate, clinicopathological variables and prognosis of epithelial ovarian tumors. METHODS: Paraffin-embedded tissue from 43 ovarian tumors of low malignant potential (LMP) and 82 primary ovarian adenocarcinomas were stained immunohistochemically for p21Cip1, p53 protein and Ki-67 antigen (a marker of cell proliferation). RESULTS: p21Cip1 levels were significantly higher in LMP tumors (p<0.001) as well as in early stage adenocarcinomas (p=0.021) and those associated with minimal residual disease (p=0.008). However, no relationship existed between p21Cip1 expression and the proliferation rate of adenocarcinomas or LMP tumors. In the vast majority of LMP tumors p21Cip1 expression was not accompanied by p53 accumulation. This p21Cip1-positive/p53-negative phenotype prevailed in the early stage (p=0.026), lower grade (p=0.018) adenocarcinomas as well as in those left with minimal residual disease (p=0.059). In patients with lower grade adenocarcinomas, decreased p21Cip1 expression was adversely related to poor overall survival on its own (p=0.0500) and when combined with p53 protein overexpression (p=0.0323). In multivariate analysis, only the stage remained as the independent predictor of survival. CONCLUSIONS: Decreased p21Cip1 expression is related to several indicators of aggressiveness in ovarian adenocarcinomas and seems to be differentially regulated in LMP tumors and adenocarcinomas. On the contrary, deregulation of p21Cip1 expression does not seem to participate in the pathogenesis of LMP tumors. Furthermore, although p21Cip1 alone or combined with p53 is of prognostic significance in lower grade adenocarcinomas, it does not appear to add to the information gained from traditional prognosticators.